HASBROUCK HEIGHTS, N.J., April 30, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce further information about the upcoming Symposium on NX-1207 to be held on May 5 at 3 p.m. in San Diego at the Annual Meeting of the American Urological Association at the San Diego Convention Center. The symposium is entitled, "Clinical studies of NX-1207: Phase 3 Injectable for BPH (Phase 2 for Prostate Cancer)," and will be held at the ICU Theater, Science and Convention Hall #2233 at the Convention Center.
The Symposium will provide news and updates on Nymox's Phase 3 Studies of NX-1207 for BPH and its Phase 2 Study of NX-1207 for Prostate Cancer, and will also provide information about safety, immunological testing, and other scientific advances for the new drug.
The keynote presentation will be given by Ronald Tutrone Jr, MD. Dr. Tutrone is the Medical Director of Chesapeake Urology Research Associates located in Baltimore, MD as well as the Chief of Urology at the Greater Baltimore Medical Center. Panel members at the Symposium will include Dr. Mohamed Bidair of San Diego CA, Dr. Susan J. Kalota of Tucson AZ, Dr. Franklin D. Gaylis of San Diego CA, Dr. Sheldon Freedman of Las Vegas, NV, Dr. Eugene Dula of Tarzana, CA, and Dr. Michael T. Gambla of Columbus OH.
Dr. Bidair is Assistant Clinical Professor at the University of California, San Diego and the Medical Director of San Diego Clinical Trials, San Diego, CA. Dr. Kalota is a highly experienced investigator at Urological Associates of Southern Arizona, Tucson, AZ. Dr. Gaylis is the Medical Director of Genesis Research at Genesis Healthcare Partners and Medical Director of the Clinical Outcomes Improvement Program at Sharp Grossmont Hospital, San Diego, CA. Dr. Freedman is a well known urologist and Medical Director of Sheldon J. Freedman, MD, Ltd, Las Vegas, NV. Dr. Dula is the Medical Director of West Coast Clinical Research and is a partner at the San Fernando Valley Urological Associates, Tarzana, CA. Dr. Gambla is President of Central Ohio Urology Group, Columbus, OH, an investigator with Columbus Urology Research, and Assistant Director of Urogynecology and Voiding Dysfunction at the Riverside Methodist Hospital, Columbus, Ohio.
NX-1207 is a novel patented drug developed by Nymox which is currently in late stage Phase 3 trials for benign prostatic hyperplasia (BPH) and Phase 2 for localized prostate cancer. NX-1207 is injected into the sector of prostate to be treated by a urologist in a clinic setting. The procedure does not require catheterization, anesthesia, or sedation, takes only a few minutes and involves little or no pain or discomfort to the patient. In multi-center U.S. clinical trials for BPH to date, a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7½ years.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com